FMP
Autolus Therapeutics plc
AUTL
NASDAQ
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
2.6 USD
-0.08 (-3.08%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
68.35M
155.58M
58.78M
46.03M
36.81M
137.37M
162.61M
192.51M
227.89M
269.78M
6.9
14.24
4.37
2.66
1.91
6.01
6.01
6.01
6.01
391.81M
460.88M
472.76M
427.38M
526.87M
771.23M
912.99M
1.08B
1.28B
1.51B
39.52
42.18
35.14
24.65
27.3
33.76
33.76
33.76
33.76
280.81M
298.72M
531.99M
755.9M
637.38M
785.12M
929.44M
1.1B
1.3B
1.54B
28.33
27.34
39.55
43.6
33.03
34.37
34.37
34.37
34.37
90.44M
117.88M
177.39M
179.82M
176.66M
240.43M
284.63M
336.95M
398.88M
472.2M
9.12
10.79
13.19
10.37
9.15
10.52
10.52
10.52
10.52
-29.56M
-15.45M
-19.84M
-37.88M
-43.97M
-47.22M
-55.89M
-66.17M
-78.33M
-92.73M
-2.98
-1.41
-1.47
-2.19
-2.28
-2.07
-2.07
-2.07
-2.07